Mallis Panagiotis, Kostakis Alkiviadis, Stavropoulos-Giokas Catherine, Michalopoulos Efstathios
Hellenic Cord Blood Bank, Biomedical Research Foundation Academy of Athens, 4 Soranou Ephessiou Street, 115 27 Athens, Greece.
Center of Experimental Surgery and Translational Research, Biomedical Research Foundation Academy of Athens, 4 Soranou Ephessiou Street, 115 27 Athens, Greece.
Bioengineering (Basel). 2020 Dec 10;7(4):160. doi: 10.3390/bioengineering7040160.
The increased demands of small-diameter vascular grafts (SDVGs) globally has forced the scientific society to explore alternative strategies utilizing the tissue engineering approaches. Cardiovascular disease (CVD) comprises one of the most lethal groups of non-communicable disorders worldwide. It has been estimated that in Europe, the healthcare cost for the administration of CVD is more than 169 billion €. Common manifestations involve the narrowing or occlusion of blood vessels. The replacement of damaged vessels with autologous grafts represents one of the applied therapeutic approaches in CVD. However, significant drawbacks are accompanying the above procedure; therefore, the exploration of alternative vessel sources must be performed. Engineered SDVGs can be produced through the utilization of non-degradable/degradable and naturally derived materials. Decellularized vessels represent also an alternative valuable source for the development of SDVGs. In this review, a great number of SDVG engineering approaches will be highlighted. Importantly, the state-of-the-art methodologies, which are currently employed, will be comprehensively presented. A discussion summarizing the key marks and the future perspectives of SDVG engineering will be included in this review. Taking into consideration the increased number of patients with CVD, SDVG engineering may assist significantly in cardiovascular reconstructive surgery and, therefore, the overall improvement of patients' life.
全球对小口径血管移植物(SDVGs)的需求不断增加,促使科学界探索利用组织工程方法的替代策略。心血管疾病(CVD)是全球最致命的非传染性疾病之一。据估计,在欧洲,心血管疾病的医疗管理成本超过1690亿欧元。常见表现包括血管狭窄或闭塞。用自体移植物替代受损血管是心血管疾病应用的治疗方法之一。然而,上述过程存在重大缺点;因此,必须探索替代血管来源。工程化的小口径血管移植物可以通过使用不可降解/可降解和天然来源的材料来生产。脱细胞血管也是小口径血管移植物开发的另一种有价值的来源。在这篇综述中,将重点介绍大量小口径血管移植物工程方法。重要的是,将全面介绍目前采用的最先进方法。本综述将包括对小口径血管移植物工程的关键标志和未来前景的讨论。考虑到心血管疾病患者数量的增加,小口径血管移植物工程可能会极大地帮助心血管重建手术,从而全面改善患者生活。